BPGbio Inc. is at the forefront of innovative biopharmaceutical development, leveraging its proprietary NAi Interrogative Biology Platform to enhance drug discovery and therapeutic development. This platform utilizes causal AI to analyze vast amounts of clinically annotated patient data, enabling the identification of biological signals and relationships that inform drug design. BPGbio's approach focuses on mitochondrial biology and protein homeostasis, with a robust pipeline that includes drug candidates like BPM31510 and BRG399, which are being evaluated for their efficacy in treating various cancers, including glioblastoma and pancreatic cancer. The company has successfully advanced several candidates through clinical trials, demonstrating the effectiveness of its AI-driven methodologies in real-world applications.

In addition to its drug development efforts, BPGbio is pioneering targeted protein degradation (TPD) technologies through its E2-based platform, which aims to address previously undruggable targets. This innovative approach allows for the design of small molecules that can selectively degrade specific proteins involved in disease processes. BPGbio's commitment to addressing unmet medical needs is further exemplified by its work on Epidermolysis Bullosa (EB), where its drug candidate BPM31510 has shown promise in improving wound healing. With over 400 patents and a strong focus on collaboration, BPGbio is positioned to make significant contributions to the fields of oncology and rare diseases, ultimately transforming patient care through advanced therapeutic solutions.

United States

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Cancer

Digestive System Diseases

Endocrine System Diseases

Genetic Diseases

Nervous System Diseases

Skin Diseases

BPGbio Inc.

Pancreatic cancer

BPG Drug #1

Biologics

Glioblastoma

BPG Drug #2

Chemotherapy Induce Alopecia

BPG Drug #3

Epidermolysis Bullosa

BPG Drug #4

Sarcopenia

BPG Drug #5

Solid tumor/s

BPG Drug #6

Huntington's disease

Parkinson's disease

BPG Drug #7

Massachusetts

Artificial Intelligence

Small Molecule Pharmaceuticals

Wound Healing

Therapeutic

BPGbio Inc.

Company Details